These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 19530698

  • 1. Isocombretastatins a versus combretastatins a: the forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent.
    Messaoudi S, Tréguier B, Hamze A, Provot O, Peyrat JF, De Losada JR, Liu JM, Bignon J, Wdzieczak-Bakala J, Thoret S, Dubois J, Brion JD, Alami M.
    J Med Chem; 2009 Jul 23; 52(14):4538-42. PubMed ID: 19530698
    [Abstract] [Full Text] [Related]

  • 2. Conformationnally restricted naphthalene derivatives type isocombretastatin A-4 and isoerianin analogues: synthesis, cytotoxicity and antitubulin activity.
    Rasolofonjatovo E, Provot O, Hamze A, Rodrigo J, Bignon J, Wdzieczak-Bakala J, Desravines D, Dubois J, Brion JD, Alami M.
    Eur J Med Chem; 2012 Jun 23; 52():22-32. PubMed ID: 22449653
    [Abstract] [Full Text] [Related]

  • 3. Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds.
    Alvarez R, Alvarez C, Mollinedo F, Sierra BG, Medarde M, Peláez R.
    Bioorg Med Chem; 2009 Sep 01; 17(17):6422-31. PubMed ID: 19647439
    [Abstract] [Full Text] [Related]

  • 4. IsoCombretaQuinazolines: Potent Cytotoxic Agents with Antitubulin Activity.
    Soussi MA, Provot O, Bernadat G, Bignon J, Desravines D, Dubois J, Brion JD, Messaoudi S, Alami M.
    ChemMedChem; 2015 Aug 01; 10(8):1392-402. PubMed ID: 26076053
    [Abstract] [Full Text] [Related]

  • 5. Novel cyanocombretastatins as potent tubulin polymerisation inhibitors.
    Jalily PH, Hadfield JA, Hirst N, Rossington SB.
    Bioorg Med Chem Lett; 2012 Nov 01; 22(21):6731-4. PubMed ID: 23010271
    [Abstract] [Full Text] [Related]

  • 6. Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells.
    Álvarez R, Gajate C, Puebla P, Mollinedo F, Medarde M, Peláez R.
    Eur J Med Chem; 2018 Oct 05; 158():167-183. PubMed ID: 30216850
    [Abstract] [Full Text] [Related]

  • 7. Pyrazolone-fused combretastatins and their precursors: synthesis, cytotoxicity, antitubulin activity and molecular modeling studies.
    Burja B, Cimbora-Zovko T, Tomić S, Jelusić T, Kocevar M, Polanc S, Osmak M.
    Bioorg Med Chem; 2010 Apr 01; 18(7):2375-87. PubMed ID: 20338766
    [Abstract] [Full Text] [Related]

  • 8. Conformationally restricted macrocyclic analogues of combretastatins.
    Mateo C, Alvarez R, Pérez-Melero C, Peláez R, Medarde M.
    Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6316-20. PubMed ID: 17889536
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and biological activity of naphthalene analogues of phenstatins: naphthylphenstatins.
    Alvarez C, Alvarez R, Corchete P, Pérez-Melero C, Peláez R, Medarde M.
    Bioorg Med Chem Lett; 2007 Jun 15; 17(12):3417-20. PubMed ID: 17434303
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. p,p-Dihydroxydihydrostilbenophanes related to antimitotic combretastatins. Conformational analysis and its relationship to tubulin inhibition.
    Álvarez R, López V, Mateo C, Medarde M, Peláez R.
    J Org Chem; 2014 Aug 01; 79(15):6840-57. PubMed ID: 24966024
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy.
    Sriram M, Hall JJ, Grohmann NC, Strecker TE, Wootton T, Franken A, Trawick ML, Pinney KG.
    Bioorg Med Chem; 2008 Sep 01; 16(17):8161-71. PubMed ID: 18722127
    [Abstract] [Full Text] [Related]

  • 13. Developments of isoCombretastatin A-4 derivatives as highly cytotoxic agents.
    Hamze A, Alami M, Provot O.
    Eur J Med Chem; 2020 Mar 15; 190():112110. PubMed ID: 32061961
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and evaluation of double bond substituted combretastatins.
    Hadfield JA, Gaukroger K, Hirst N, Weston AP, Lawrence NJ, McGown AT.
    Eur J Med Chem; 2005 Jun 15; 40(6):529-41. PubMed ID: 15922837
    [Abstract] [Full Text] [Related]

  • 15. Discovery of azaisoerianin derivatives as potential antitumors agents.
    Soussi MA, Provot O, Bernadat G, Bignon J, Wdzieczak-Bakala J, Desravines D, Dubois J, Brion JD, Messaoudi S, Alami M.
    Eur J Med Chem; 2014 May 06; 78():178-89. PubMed ID: 24681982
    [Abstract] [Full Text] [Related]

  • 16. E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory beta-E-nitrostyrenes.
    Pettit RK, Pettit GR, Hamel E, Hogan F, Moser BR, Wolf S, Pon S, Chapuis JC, Schmidt JM.
    Bioorg Med Chem; 2009 Sep 15; 17(18):6606-12. PubMed ID: 19709889
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. cis-Restricted 3-aminopyrazole analogues of combretastatins: synthesis from plant polyalkoxybenzenes and biological evaluation in the cytotoxicity and phenotypic sea urchin embryo assays.
    Tsyganov DV, Konyushkin LD, Karmanova IB, Firgang SI, Strelenko YA, Semenova MN, Kiselyov AS, Semenov VV.
    J Nat Prod; 2013 Aug 23; 76(8):1485-91. PubMed ID: 23924236
    [Abstract] [Full Text] [Related]

  • 19. Evading Pgp activity in drug-resistant cancer cells: a structural and functional study of antitubulin furan metotica compounds.
    Nguyen TL, Cera MR, Pinto A, Lo Presti L, Hamel E, Conti P, Gussio R, De Wulf P.
    Mol Cancer Ther; 2012 May 23; 11(5):1103-11. PubMed ID: 22442310
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis, and cytotoxicity of novel 3-arylidenones derived from alicyclic ketones.
    Satam V, Bandi RK, Behera AK, Mishra BK, Tzou S, Brockway O, Babu B, Zeller M, Westbrook C, Mooberry SL, Lee M, Pati H.
    Chem Biol Drug Des; 2011 Oct 23; 78(4):700-8. PubMed ID: 21752198
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.